New version of classification of pulmonary hypertension

Czech version

Authors: Michael Aschermann
Authors‘ workplace: II. interní klinika 1. LF UK a VFN Praha, přednosta prof. MUDr. Aleš Linhart, DrSc., FESC, FCMA
Published in: Vnitř Lék 2015; 61(5): 387-391
Category: Reviews

Overview

Pulmonary hypertension has multifactorial pathophysiology with endothelial dysfunction, vasoconstriction, pulmonary vessel wall remodeling and plexiform lesions contributing to increased pulmonary vascular resistance. Recent studies showed the importance of several mediators in PH pathophysiology, including prostacyclin, nitric oxide, serotonine, endothelin 1, several cytokines, chemokines, as well as members of the transforming growth factor β family (TGF-β). Current article summarizes new classification version of pulmonary hypertension, which was presented at World pulmonary hypertension symposium in 2013. This classification has five main groups with similar pathological findings, hemodynamic characteristics and similar management.

Key words:
classification –⁠ pulmonary arterial hypertension –⁠ pulmonary hypertension

Sources

1. Simonneau G, Gatzoulis MA, Adatia I et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62(25 Suppl): D34-D41.

2. Lane KB, Machado RD, Pauciulo MW et al. International PPH Consortium. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000; 26(1): 81–84.

3. Machado RD, Pauciulo MW, Thomson JR et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 2001; 68(1): 92–102.

4. Thomson JR, Machado RD, Pauciulo MW et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family. J Med Genet 2000; 37(10): 741–745.

5. Loscalzo J. Genetic clues to the cause of primary pulmonary hypertension. N Engl J Med 2001; 345(5): 367–371.

6. Loyd JE, Butler MG, Foroud TM et al. Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 152(1): 93–97.

7. Trembath RC, Thomson JR, Machado RD et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001; 345(5): 325–334.

8. Soubrier F, Chung WK, Machado R et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll cardiol 2013; 62(25 Suppl): D13-D21.

9. Savale L, Chaumais MC, Cottin V et al. Pulmonary hypertension with benfluorex exposure. Eur Respir J 2012; 40(5): 1164–1172.

10. Montani D, Bergot E, Gunther S et al. Pulmonary hypertension in patients treated by dasatinib. Circulation 2011; 125(17): 2128–2137.

11. Wijson KL, Zelig CM, Harvey JP et al. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am J Perinatol 2011; 28(1): 19–24.

12. MacGregor AJ, Canavan R, Knight C et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2001; 40(4): 453–459.

13. Stupi AM, Steen VD, Owens GR et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986; 29(4): 515–524.

14. Valerio CJ, Schreiber BE, Handler CE et al. Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension. Arthritis Rheum 2013; 65(4): 1074–1084.

15. Degado B, Yaici A, Le Pavec J et al. Long term effect of bosentan in patients with HIV-associated pulmonary hypertension. Eur Respir J 2009; 33(1): 92–98.

16. Sitbon O, Lascoux-Combe C, Delfraissy JF et al. Prevalence of HIV-related pulmonary hypertension in the current antiretroviral therapy era. Am J Respir Care Med 2008; 177(1): 108–113.

17. Engelfreit PM, Duffels MG, Möller T et al. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. Heart 2007; 93(6): 682–687.

18. Dos Santos Fernandez CJ, Jardim CV, Hovnanian A et al. Survival in schistosomiasis-associated pulmonary arterial hypertension. J Am Coll Cardiol 2010; 56(9): 715–720.